11:31am Tuesday 24 October 2017

TITRATION study confirms LCZ696 safe and tolerated in clinical practice

The TITRATION study has confirmed that LCZ696 is safe and tolerated by patients with heart failure and reduced ejection fraction (HFrEF) in clinical practice, announced principal investigator Dr Michele Senni in a late breaking trials session today at Heart Failure 2015

Seville, Spain –  The TITRATION study has confirmed that LCZ696 is safe and tolerated by patients with heart failure and reduced ejection fraction (HFrEF) in clinical practice, announced principal investigator Dr Michele Senni in a late breaking trials session today at Heart Failure 2015. More than 70% of patients achieved the target dose 200 mg BID over a 3- or 6-week up-titration regimen.

“At the end of the study patients asked us to continue LCZ696 because they felt better.”

Heart Failure 2015 is the main annual meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). The scientific programme is here.

Dr Senni, who is head of the Cardiology, Heart Failure and Heart Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, and national leader of PARADIGM-HF, said: “When you are treating patients you need to be confident with a new drug. The PARADIGM-HF trial demonstrated the superiority of LCZ696, an angiotensin receptor neprilysin inhibitor, over the ACE inhibitor enalapril in reducing the risk of cardiovascular mortality and heart failure hospitalisation.1 Moreover it prevented clinical progression in patients with HFrEF. The TITRATION study was designed to evaluate the practical application of LCZ696 in the clinic.”

TITRATION was a randomised, double blind study that assessed the safety and tolerability of initiating and up-titrating LCZ696 from 50mg BID to a target dose of 200mg BID in a 3-week (condensed) versus 6-week (conservative) regimen in patients with HFrEF (ejection fraction ≤35%). The study enrolled a broader range of patients than the PARADIGM-HF trial, including inpatients and patients naïve to ACE inhibitors or angiotensin receptor blockers (ARBs).

The study was conducted in two phases. The first was an open label run in period in which LCZ696 was tested for tolerability and safety at a dosage of 50 mg BID for 5 days. Patients were then randomised 1:1 to LCZ696 in a conservative up-titration over 6 weeks versus a condensed up-titration over 3 weeks. In both groups the target dose was 200 mg BID.

Primary endpoints were the proportion of patients experiencing pre-specified adverse events (symptomatic hypotension, hyperkalaemia, renal dysfunction, angioedema) and laboratory outcomes including systolic blood pressure <95 mmHg and a doubling of serum creatinine from baseline. Secondary endpoints included the number of patients achieving the target dose without any down-titration or interruption over 12 weeks (defined as treatment success).

Of the 540 patients enrolled in the run in, 498 (92%) were randomised and of those, 429 (86%) completed the study. There were no differences in the primary endpoints between groups. After excluding patients who discontinued LCZ696 because of non-adverse events or death, treatment success was achieved in 78% and 84% of patients in the condensed and conservative regimens, respectively (p=0.07).

Dr Senni said:

“At least 76% of randomised patients achieved and maintained the target dose of LCZ696 200mg BID, regardless of the up-titration regimen. The target dose was also achieved for at least 2 weeks leading to study completion in 80% of patients including those requiring a temporary down-titration or dose interruption during the study. Commonly reported adverse events in the TITRATION study were in line with the LCZ696 group in the PARADIGM-HF trial, confirming those findings in real life.”

He added:

“This study provides complementary data beyond PARADIGM-HF to support the use of LCZ696 in clinical practice in a broader range of patients such as inpatients and patients naïve to ACE inhibitors and ARBs, which largely mimics the real life situation. Both regimens reached a very high rate of treatment success and tolerability.”

Dr Senni concluded:

“We expect LCZ696 to be on the market in Europe and the US within the coming year which is good news. At the end of the study patients asked us to continue LCZ696 because they felt better. TITRATION was an open label study so we know patients were taking the drug. We have seen in real life that switching to LCZ696 is beneficial for patients.”

ENDS

References

1McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.

Notes to editor

SOURCES OF FUNDING: The study was sponsored by Novartis

DISCLOSURES: Professor Michele Senni is a consultant for Novartis and Abbot Vascular, and has also received honoraria. He has also received speaking honoraria from Novartis and Abbot Vascular.

 

About the Heart Failure Association
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

The Heart Failure Association (HFA) is a registered branch of the ESC. Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

Information for journalists attending Heart Failure 2015
Heart Failure 2015 will be held 23 to 26 May in Seville, Spain, at the Sevilla Palacio de Congresos. The full scientific programme is available here

•    Free registration applies to press representatives upon receipt of valid credentials and a fully completed embargo form. (to be sent to press@escardio.org)
•    Credential: A valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event). The ESC media and embargo policy is here
•    The ESC Press Office will check your credential and confirm your press accreditation by email.
•    Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives
•    The decision of the ESC Press Office is final regarding all press registration requests.
•    The ESC Press Office will verify the documents and confirm by email that your Press Accreditation is valid.


Share on:
or:

Health news